NCT03907475 2026-03-18
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
OHSU Knight Cancer Institute
Genentech, Inc.
Eikon Therapeutics
M.D. Anderson Cancer Center
Australasian Gastro-Intestinal Trials Group
Genentech, Inc.
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Novartis
Bristol-Myers Squibb
AstraZeneca
Indiana University
INSYS Therapeutics Inc